Table 1.

Esketamine and TMS identification

Concept ID	Description
2119365 (Ingredient)	Esketamine
G2083 (Procedure)	Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self‐administration
G2082 (Procedure)	Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self‐administration
0310T (Procedure)	Motor function mapping using noninvasive navigated transcranial magnetic stimulation (nTMS) for therapeutic treatment planning, upper and lower extremity
0161T (Procedure)	Therapeutic repetitive transcranial magnetic stimulation treatment delivery and management, per session
0160T (Procedure)	Therapeutic repetitive transcranial magnetic stimulation treatment planning
90867 (Procedure)	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management
90868 (Procedure)	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session
90869 (Procedure)	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold redetermination with delivery and management